Genome-wide sequencing for the identification of potential genomic denominators between tumorgenesis factors in neuroblastoma and differentiated thyroid carcinoma in children

Genome-wide sequencing for the identification of potential genomic denominators between tumorgenesis factors in neuroblastoma and differentiated thyroid carcinoma in children - Genetic research into thyroid cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON40506

Enrollment

Registered

2014-01-16

Start date

2014-01-31

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

differentiated thyroid carcinoma Thyroid cancer

Interventions

None listed

Eligibility

Age

2 Years to 99 Years

Inclusion criteria

Inclusion criteria: Neuroblastoma patients treated with 131I-MIBG who developed differentiated thyroid carcinoma (and their parents

Exclusion criteria

Exclusion criteria: Treatment with external irradiation

Design outcomes

Primary

Measure	Time frame
To identify variants and structural variations that determine increased risk for secondary thyroid cancer. De novo germline aberrations as well as germline aberrations compared to the reference genome will be identified. In addition we will determine the somatic variants found in the tumor sample.	—

Secondary

Measure	Time frame
-	—

Countries

Netherlands

Outcome results